Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 15, 2025
Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO
GlobeNewswire
·
April 15, 2025
JERUSALEM, April 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced highlights from Dr. Rachel B Wagman’s oral presentation at the 2025 World Congress on …
Biomerica Reports Third Quarter Fiscal 2025 Financial Results
GlobeNewswire
·
April 15, 2025
Total Revenue Increases 10% Year-Over-Year Delivers Improved Gross Margins, Achieves Annual Cost Savings Target Early, and Reduces Cash Burn Over 55% IRVINE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a …
Best Probiotic for Bloating and Gas 2025 - Top Probiotic Supplements for Gut Health from YourBiology
GlobeNewswire
·
April 15, 2025
GLASGOW, United Kingdom, April 15, 2025 (GLOBE NEWSWIRE) -- Struggling with constant bloating, gas, or an upset stomach? You’re not alone. Digestive discomfort can affect anyone, but the good news is that the right probiotic can help restore balance to …
Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market
GlobeNewswire
·
April 15, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injury New and improved features streamline user …
Annual General Meeting of Kuros Biosciences approves all resolutions
GlobeNewswire
·
April 15, 2025
Annual General Meeting of Kuros Biosciences approves all resolutions Schlieren (Zurich), Switzerland, April 15, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, held its Annual General Meeting today …
Ashvattha Therapeutics to Present at ARVO, Retina World Congress, and AOS Annual Meeting
GlobeNewswire
·
April 15, 2025
REDWOOD CITY, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in …
Artios Pharma Announces Details of Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
April 15, 2025
CAMBRIDGE, United Kingdom and NEW YORK, April 15, 2025 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today announced that the company’s abstract featuring clinical …
Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
GlobeNewswire
·
April 15, 2025
New indications discovered by applying active machine learning and using samples from the company’s vast biobank of live-cell tumors specimens Builds upon Predictive’s biomarker discovery platform to select targeted patient cohorts to significantly de-risk …
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
GlobeNewswire
·
April 15, 2025
Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210 US $15M milestone payment from Merck extends company’s cash runway to …
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
GlobeNewswire
·
April 15, 2025
NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the EASL …
Extendicare Announces April 2025 Dividend of C$0.042 per Share
GlobeNewswire
·
April 15, 2025
MARKHAM, Ontario, April 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company (the “Common Share”) for the month of April 2025, …
Hydreight Technologies Expands GLP-1 Telehealth Suite with Launch of Liraglutide on VSDHOne Platform
GlobeNewswire
·
April 15, 2025
VANCOUVER, British Columbia and LAS VEGAS, April 15, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight”or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing mobile clinical network and medical platform which enables …
Lisata Therapeutics Announces Research License with Catalent
GlobeNewswire
·
April 15, 2025
BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other …
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
GlobeNewswire
·
April 15, 2025
Precise Volume Measurement Prior to Discharge Identifies Mortality Risk Oak Ridge, TN, April 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced compelling new data …
Avalon GloboCare Partners with SpecialtyHealth, Inc. to Power Police Chiefs’ Fitness Challenge with KetoAir
GlobeNewswire
·
April 15, 2025
FREEHOLD, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced the addition of …
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
GlobeNewswire
·
April 15, 2025
In combination with atezolizumab or durvalumab Study conducted under the CRADA agreement between NCI and Oryzon MADRID and CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage …
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025
GlobeNewswire
·
April 15, 2025
HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, …
Mural Oncology Announces Plans to Explore Strategic Alternatives
GlobeNewswire
·
April 15, 2025
Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans …
FluidForm Bio™ Advances Vascularized Tissue Engineering with New FRESH™ 3D Bioprinting Breakthrough
GlobeNewswire
·
April 15, 2025
WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced a major advancement in vascularized tissue engineering. A newly published study in ACS Biomaterials …
FDA Clears Ceribell’s Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older
GlobeNewswire
·
April 15, 2025
SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U …